ADBiotech Balance Sheet Health
Financial Health criteria checks 3/6
ADBiotech has a total shareholder equity of ₩4.4B and total debt of ₩10.1B, which brings its debt-to-equity ratio to 229.3%. Its total assets and total liabilities are ₩22.0B and ₩17.6B respectively.
Key information
229.3%
Debt to equity ratio
₩10.13b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩3.32b |
| Equity | ₩4.42b |
| Total liabilities | ₩17.61b |
| Total assets | ₩22.03b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A179530's short term assets (₩7.8B) do not cover its short term liabilities (₩13.6B).
Long Term Liabilities: A179530's short term assets (₩7.8B) exceed its long term liabilities (₩4.0B).
Debt to Equity History and Analysis
Debt Level: A179530's net debt to equity ratio (154.1%) is considered high.
Reducing Debt: Insufficient data to determine if A179530's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable A179530 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: A179530 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 43.2% per year.